Proteomic identification of specifically carbonylated brain proteins in APP NLh/APP NLh×PS-1 P264L/PS-1 P264L human double mutant knock-in mice model of Alzheimer disease as a function of age

Journal of Proteomics

Volumn 74, Issue 11, 2011, Pages 2430-2440

  Sultana, Rukhsana ^a   Robinson, Renã A S ^a   Di Domenico, Fabio ^b   Abdul, Hafiz Mohmmad ^a   St Clair, Daret K ^a   Markesbery, William R ^c   Cai, Jian ^d   Pierce, William M ^d   Butterfield, D Allan ^a  

^a UNIVERSITY OF KENTUCKY   (United States)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c UNIVERSITY OF KENTUCKY   (United States)

^d UNIVERSITY OF LOUISVILLE   (United States)

Author keywords

Alzheimer's disease; Amyloid peptide; Oxidative stress; Presenilin 1; Protein carbonyls; Redox proteomics

Indexed keywords

ALPHA ENOLASE; AMYLOID PRECURSOR PROTEIN; BETA ACTIN; BETA SYNUCLEIN; BRAIN PROTEIN; PRESENILIN; PROTEIN 14 3 3; PROTON TRANSPORTING ADENOSINE TRIPHOSPHATE SYNTHASE; PYRUVATE DEHYDROGENASE;

AGE; AGE DISTRIBUTION; ALPHA CHAIN; ALZHEIMER DISEASE; AMINO ACID SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL FUNCTION; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE COURSE; MALE; MASS SPECTROMETRY; MOLECULAR WEIGHT; MOUSE; MOUSE MUTANT; NEWBORN; NONHUMAN; OXIDATION; OXIDATIVE STRESS; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN CARBONYLATION; PROTEIN FUNCTION; PROTEIN MODIFICATION; PROTEOMICS; WILD TYPE;

AGE FACTORS; ALZHEIMER DISEASE; AMINO ACID SUBSTITUTION; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; BRAIN; BRAIN CHEMISTRY; DISEASE MODELS, ANIMAL; GENE KNOCK-IN TECHNIQUES; HUMANS; LEUCINE; MALE; MICE; MICE, TRANSGENIC; NERVE TISSUE PROTEINS; PRESENILIN-1; PROLINE; PROTEIN CARBONYLATION; PROTEIN STRUCTURE, TERTIARY; PROTEOMICS;

MUS;

EID: 80054871710     PISSN: 18743919     EISSN: 18767737     Source Type: Journal    
DOI: 10.1016/j.jprot.2011.06.015     Document Type: Article

References (100)

1. Mebane-Sims I. 2009 Alzheimer's disease facts and figures. Alzheimers Dement 2009, 5:234-270.
2. Katzman R., Saitoh T. Advances in Alzheimer's disease. FASEB J 1991, 5:278-286.
3. Butterfield D.A., Drake J., Pocernich C., Castegna A. Evidence of oxidative damage in Alzheimer's disease brain: central role for amyloid beta-peptide. Trends Mol Med 2001, 7:548-554.
4. Butterfield D.A., Lauderback C.M. Lipid peroxidation and protein oxidation in Alzheimer's disease brain: potential causes and consequences involving amyloid beta-peptide-associated free radical oxidative stress. Free Radic Biol Med 2002, 32:1050-1060.
5. Markesbery W.R. Oxidative stress hypothesis in Alzheimer's disease. Free Radic Biol Med 1997, 23:134-147.
6. Scheuner D., Eckman C., Jensen M., Song X., Citron M., Suzuki N., et al. Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease. Nat Med 1996, 2:864-870.
7. Sturchler-Pierrat C., Abramowski D., Duke M., Wiederhold K.H., Mistl C., Rothacher S., et al. Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology. Proc Natl Acad Sci USA 1997, 94:13287-13292.
8. Lott I.T., Head E. Alzheimer disease and Down syndrome: factors in pathogenesis. Neurobiol Aging 2005, 26:383-389.
9. Butterfield D.A., Bader Lange M.L., Sultana R. Involvements of the lipid peroxidation product, HNE, in the pathogenesis and progression of Alzheimer's disease. Biochim Biophys Acta 2010, 1801:924-929.
10. Hensley K., Hall N., Subramaniam R., Cole P., Harris M., Aksenov M., et al. Brain regional correspondence between Alzheimer's disease histopathology and biomarkers of protein oxidation. J Neurochem 1995, 65:2146-2156.
11. Mecocci P., MacGarvey U., Beal M.F. Oxidative damage to mitochondrial DNA is increased in Alzheimer's disease. Ann Neurol 1994, 36:747-751.
12. Nunomura A., Perry G., Aliev G., Hirai K., Takeda A., Balraj E.K., et al. Oxidative damage is the earliest event in Alzheimer disease. J Neuropathol Exp Neurol 2001, 60:759-767.
13. Wang J., Xiong S., Xie C., Markesbery W.R., Lovell M.A. Increased oxidative damage in nuclear and mitochondrial DNA in Alzheimer's disease. J Neurochem 2005, 93:953-962.
14. Berlett B.S., Stadtman E.R. Protein oxidation in aging, disease, and oxidative stress. J Biol Chem 1997, 272:20313-20316.
15. Dalle-Donne I., Giustarini D., Colombo R., Rossi R., Milzani A. Protein carbonylation in human diseases. Trends Mol Med 2003, 9:169-176.
16. Smith C.D., Carney J.M., Starkereed P.E., Oliver C.N., Stadtman E.R., Floyd R.A., et al. Excess brain protein oxidation and enzyme dysfunction in normal aging and in Alzheimer-disease. P Natl Acad Sci USA 1991, 88:10540-10543.
17. Winterbourn C.C., Buss I.H. Protein carbonyl measurement by enzyme-linked immunosorbent assay. Methods Enzymol 1999, 300:106-111.
18. Dalle-Donne I., Rossi R., Giustarini D., Milzani A., Colombo R. Protein carbonyl groups as biomarkers of oxidative stress. Clin Chim Acta 2003, 329:23-38.
19. Stadtman E.R., Levine R.L. Free radical-mediated oxidation of free amino acids and amino acid residues in proteins. Amino Acids 2003, 25:207-218.
20. Butterfield D.A., Stadtman E.R. Protein oxidation processes in aging brain. Adv Cell Aging Gerontol 1997, 2:161-191.
21. Picklo M.J., Montine T.J., Amarnath V., Neely M.D. Carbonyl toxicology and Alzheimer's disease. Toxicol Appl Pharmacol 2002, 184:187-197.
22. Smith M.A., Sayre L.M., Anderson V.E., Harris P.L., Beal M.F., Kowall N., et al. Cytochemical demonstration of oxidative damage in Alzheimer disease by immunochemical enhancement of the carbonyl reaction with 2,4-dinitrophenylhydrazine. J Histochem Cytochem 1998, 46:731-735.
23. Ansari M.A., Scheff S.W. Oxidative stress in the progression of Alzheimer disease in the frontal cortex. J Neuropathol Exp Neurol 2010, 69:155-167.
24. Castegna A., Aksenov M., Aksenova M., Thongboonkerd V., Klein J.B., Pierce W.M., et al. Proteomic identification of oxidatively modified proteins in Alzheimer's disease brain. Part I: creatine kinase BB, glutamine synthase, and ubiquitin carboxy-terminal hydrolase L-1. Free Radic Biol Med 2002, 33:562-571.
25. Castegna A., Aksenov M., Thongboonkerd V., Klein J.B., Pierce W.M., Booze R., et al. Proteomic identification of oxidatively modified proteins in Alzheimer's disease brain. Part II: dihydropyrimidinase-related protein 2, alpha-enolase and heat shock cognate 71. J Neurochem 2002, 82:1524-1532.
26. Castegna A., Thongboonkerd V., Klein J.B., Lynn B., Markesbery W.R., Butterfield D.A. Proteomic identification of nitrated proteins in Alzheimer's disease brain. J Neurochem 2003, 85:1394-1401.
27. Reaume A.G., Howland D.S., Trusko S.P., Savage M.J., Lang D.M., Greenberg B.D., et al. Enhanced amyloidogenic processing of the beta-amyloid precursor protein in gene-targeted mice bearing the Swedish familial Alzheimer's disease mutations and a "humanized" Abeta sequence. J Biol Chem 1996, 271:23380-23388.
28. Siman R., Reaume A.G., Savage M.J., Trusko S., Lin Y.G., Scott R.W., et al. Presenilin-1 P264L knock-in mutation: differential effects on abeta production, amyloid deposition, and neuronal vulnerability. J Neurosci 2000, 20:8717-8726.
29. Borchelt D.R., Ratovitski T., van Lare J., Lee M.K., Gonzales V., Jenkins N.A., et al. Accelerated amyloid deposition in the brains of transgenic mice coexpressing mutant presenilin 1 and amyloid precursor proteins. Neuron 1997, 19:939-945.
30. Anantharaman M., Tangpong J., Keller J.N., Murphy M.P., Markesbery W.R., Kiningham K.K., et al. Beta-amyloid mediated nitration of manganese superoxide dismutase: implication for oxidative stress in a APPNLH/NLH×PS-1P264L/P264L double knock-in mouse model of Alzheimer's disease. Am J Pathol 2006, 168:1608-1618.
31. Bader Lange M.L., St Clair D., Markesbery W.R., Studzinski C.M., Murphy M.P., Butterfield D.A. Age-related loss of phospholipid asymmetry in APP(NLh)/APP(NLh)×PS-1(P264L)/PS-1(P264L) human double mutant knock-in mice: relevance to Alzheimer disease. Neurobiol Dis 2010, 38:104-115.
32. Mohmmad Abdul H., Sultana R., Keller J.N., St Clair D.K., Markesbery W.R., Butterfield D.A. Mutations in amyloid precursor protein and presenilin-1 genes increase the basal oxidative stress in murine neuronal cells and lead to increased sensitivity to oxidative stress mediated by amyloid beta-peptide (1-42), HO and kainic acid: implications for Alzheimer's disease. J Neurochem 2006, 96:1322-1335.
33. Thongboonkerd V., Luengpailin J., Cao J., Pierce W.M., Cai J., Klein J.B., et al. Fluoride exposure attenuates expression of Streptococcus pyogenes virulence factors. J Biol Chem 2002, 277:16599-16605.
34. Dalle-Donne I., Scaloni A., Butterfield D.A. Redox proteomics: from protein modifications to cellular dysfunction and diseases 2006, John Wiley and Sons, Hoboken, NJ.
35. Abdul H.M., Sultana R., St Clair D.K., Markesbery W.R., Butterfield D.A. Oxidative damage in brain from human mutant APP/PS-1 double knock-in mice as a function of age. Free Radic Biol Med 2008, 45:1420-1425.
36. Pollard T.D., Borisy G.G. Cellular motility driven by assembly and disassembly of actin filaments. Cell 2003, 112:453-465.
37. Carlier M.F., Pantaloni D. Control of actin assembly dynamics in cell motility. J Biol Chem 2007, 282:23005-23009.
38. Kasai H., Fukuda M., Watanabe S., Hayashi-Takagi A., Noguchi J. Structural dynamics of dendritic spines in memory and cognition. Trends Neurosci 2010, 33:121-129.
39. Holtmaat A., Svoboda K. Experience-dependent structural synaptic plasticity in the mammalian brain. Nat Rev Neurosci 2009, 10:647-658.
40. Schubert V., Dotti C.G. Transmitting on actin: synaptic control of dendritic architecture. J Cell Sci 2007, 120:205-212.
41. Sheng M., Hoogenraad C.C. The postsynaptic architecture of excitatory synapses: a more quantitative view. Annu Rev Biochem 2007, 76:823-847.
42. Renner M., Specht C.G., Triller A. Molecular dynamics of postsynaptic receptors and scaffold proteins. Curr Opin Neurobiol 2008, 18:532-540.
43. Schlager M.A., Hoogenraad C.C. Basic mechanisms for recognition and transport of synaptic cargos. Mol Brain 2009, 2:25.
44. Bramham C.R. Local protein synthesis, actin dynamics, and LTP consolidation. Curr Opin Neurobiol 2008, 18:524-531.
45. Hering H., Sheng M. Activity-dependent redistribution and essential role of cortactin in dendritic spine morphogenesis. J Neurosci 2003, 23:11759-11769.
46. Ivanov A., Esclapez M., Pellegrino C., Shirao T., Ferhat L. Drebrin A regulates dendritic spine plasticity and synaptic function in mature cultured hippocampal neurons. J Cell Sci 2009, 122:524-534.
47. van Woerden G.M., Hoebeek F.E., Gao Z., Nagaraja R.Y., Hoogenraad C.C., Kushner S.A., et al. betaCaMKII controls the direction of plasticity at parallel fiber-Purkinje cell synapses. Nat Neurosci 2009, 12:823-825.
48. Wu L.J., Ren M., Wang H., Kim S.S., Cao X., Zhuo M. Neurabin contributes to hippocampal long-term potentiation and contextual fear memory. PLoS One 2008, 3:e1407.
49. Newey S.E., Velamoor V., Govek E.E., Van Aelst L. Rho GTPases, dendritic structure, and mental retardation. J Neurobiol 2005, 64:58-74.
50. Perluigi M., Sultana R., Cenini G., Di Domenico F., Memo M., Pierce W.M., et al. Redox proteomics identification of HNE-modified brain proteins in alzheimer's disease: role of lipid peroxidation in Alzheimer's disease pathogenesis. Prot. Clin. Appli. 2009, l 3:682-693.
51. Reed T., Perluigi M., Sultana R., Pierce W.M., Klein J.B., Turner D.M., et al. Redox proteomic identification of 4-hydroxy-2-nonenal-modified brain proteins in amnestic mild cognitive impairment: insight into the role of lipid peroxidation in the progression and pathogenesis of Alzheimer's disease. Neurobiol Dis 2008, 30:107-120.
52. Sultana R., Boyd-Kimball D., Poon H.F., Cai J., Pierce W.M., Klein J.B., et al. Redox proteomics identification of oxidized proteins in Alzheimer's disease hippocampus and cerebellum: an approach to understand pathological and biochemical alterations in AD. Neurobiol Aging 2006, 27:1564-1576.
53. Sultana R., Butterfield D.A. Oxidatively modified GST and MRP1 in Alzheimer's disease brain: implications for accumulation of reactive lipid peroxidation products. Neurochem Res 2004, 29:2215-2220.
54. Planel E., Miyasaka T., Launey T., Chui D.H., Tanemura K., Sato S., et al. Alterations in glucose metabolism induce hypothermia leading to tau hyperphosphorylation through differential inhibition of kinase and phosphatase activities: implications for Alzheimer's disease. J Neurosci 2004, 24:2401-2411.
55. Mosconi L., Mistur R., Switalski R., Tsui W.H., Glodzik L., Li Y., et al. FDG-PET changes in brain glucose metabolism from normal cognition to pathologically verified Alzheimer's disease. Eur J Nucl Med Mol Imaging 2009, 36:811-822.
56. Gibson G.E., Sheu K.F., Blass J.P., Baker A., Carlson K.C., Harding B., et al. Reduced activities of thiamine-dependent enzymes in the brains and peripheral tissues of patients with Alzheimer's disease. Arch Neurol 1988, 45:836-840.
57. Parnetti L., Gaiti A., Polidori M.C., Brunetti M., Palumbo B., Chionne F., et al. Increased cerebrospinal fluid pyruvate levels in Alzheimer's disease. Neurosci Lett 1995, 199:231-233.
58. Parnetti L., Reboldi G.P., Gallai V. Cerebrospinal fluid pyruvate levels in Alzheimer's disease and vascular dementia. Neurology 2000, 54:735-737.
59. Cecarini V., Ding Q., Keller J.N. Oxidative inactivation of the proteasome in Alzheimer's disease. Free Radic Res 2007, 41:673-680.
60. Keller J.N., Hanni K.B., Markesbery W.R. Impaired proteasome function in Alzheimer's disease. J Neurochem 2000, 75:436-439.
61. Balcz B., Kirchner L., Cairns N., Fountoulakis M., Lubec G. Increased brain protein levels of carbonyl reductase and alcohol dehydrogenase in Down syndrome and Alzheimer's disease. J Neural Trans 2001, 193-201.
62. Butterfield D.A., Lange M.L. Multifunctional roles of enolase in Alzheimer's disease brain: beyond altered glucose metabolism. J Neurochem 2009, 111:915-933.
63. Choi J., Forster M.J., McDonald S.R., Weintraub S.T., Carroll C.A., Gracy R.W. Proteomic identification of specific oxidized proteins in ApoE-knockout mice: relevance to Alzheimer's disease. Free Radic Biol Med 2004, 36:1155-1162.
64. Korolainen M.A., Goldsteins G., Nyman T.A., Alafuzoff I., Koistinaho J., Pirttila T. Oxidative modification of proteins in the frontal cortex of Alzheimer's disease brain. Neurobiol Aging 2006, 27:42-53.
65. Sultana R., Poon H.F., Cai J., Pierce W.M., Merchant M., Klein J.B., et al. Identification of nitrated proteins in Alzheimer's disease brain using a redox proteomics approach. Neurobiol Dis 2006, 22:76-87.
66. Sultana R., Reed T., Perluigi M., Coccia R., Pierce W.M., Butterfield D.A. Proteomic identification of nitrated brain proteins in amnestic mild cognitive impairment: a regional study. J Cell Mol Med 2007, 11:839-851.
67. Boyd-Kimball D., Sultana R., Poon H.F., Lynn B.C., Casamenti F., Pepeu G., et al. Proteomic identification of proteins specifically oxidized by intracerebral injection of amyloid beta-peptide (1-42) into rat brain: implications for Alzheimer's disease. Neurosci 2005, 132:313-324.
68. Opii W.O., Nukala V.N., Sultana R., Pandya J.D., Day K.M., Merchant M.L., et al. Proteomic identification of oxidized mitochondrial proteins following experimental traumatic brain injury. J Neurotrauma 2007, 24:772-789.
69. Ko A.C., Hernandez J., Brinton J.P., Faidley E.A., Mugge S.A., Mets M.B., et al. Anti-gamma-enolase autoimmune retinopathy manifesting in early childhood. Arch Ophthalmol 2010, 128:1590-1595.
70. Sergeant N., Wattez A., Galvan-valencia M., Ghestem A., David J.P., Lemoine J., et al. Association of ATP synthase alpha-chain with neurofibrillary degeneration in Alzheimer's disease. Neurosci 2003, 117:293-303.
71. Molina J.A., de Bustos F., Jimenez-Jimenez F.J., Benito-Leon J., Gasalla T., Orti-Pareja M., et al. Respiratory chain enzyme activities in isolated mitochondria of lymphocytes from patients with Alzheimer's disease. Neurology 1997, 48:636-638.
72. Busciglio J., Pelsman A., Wong C., Pigino G., Yuan M., Mori H., et al. Altered metabolism of the amyloid beta precursor protein is associated with mitochondrial dysfunction in Down's syndrome. Neuron 2002, 33:677-688.
73. Caspersen C., Wang N., Yao J., Sosunov A., Chen X., Lustbader J.W., et al. Mitochondrial Abeta: a potential focal point for neuronal metabolic dysfunction in Alzheimer's disease. FASEB J 2005, 19:2040-2041.
74. Reddy P.H. Amyloid beta, mitochondrial structural and functional dynamics in Alzheimer's disease. Exp Neurol 2009, 218:286-292.
75. Ankarcrona M., Mangialasche F., Winblad B. Rethinking Alzheimer's disease therapy: are mitochondria the key?. J Alzheimers Dis 2010, 20(Suppl 2):S579-S590.
76. Sultana R., Butterfield D.A. Oxidatively modified, mitochondria-relevant brain proteins in subjects with Alzheimer disease and mild cognitive impairment. J Bioenerg Biomembr 2009, 41:441-446.
77. Sultana R., Mecocci P., Mangialasche F., Cecchetti R., Baglioni M., Butterfield D.A. Increased protein and lipid oxidative damage in mitochondria isolated from lymphocytes from patients with Alzheimer disease: insights into the role of oxidative stress in ad and initial investigations into a potential biomarker for this dementing disorder. J Alz Dis 2011, 24:77-84.
78. Messier C., Gagnon M. Glucose regulation and cognitive functions: relation to Alzheimer's disease and diabetes. Behav Brain Res 1996, 75:1-11.
79. Vanhanen M., Soininen H. Glucose intolerance, cognitive impairment and Alzheimer's disease. Curr Opin Neurol 1998, 11:673-677.
80. Hoyer S. Memory function and brain glucose metabolism. Pharmacopsychiatry 2003, 36(Suppl 1):S62-S67.
81. Chen Y., Jungsuwadee P., Vore M., Butterfield D.A., St Clair D.K. Collateral damage in cancer chemotherapy: oxidative stress in nontargeted tissues. Mol Interv 2007, 7:147-156.
82. Dougherty M.K., Morrison D.K. Unlocking the code of 14-3-3. J Cell Sci 2004, 117:1875-1884.
83. Takahashi Y. The 14-3-3 proteins: gene, gene expression, and function. Neurochem Res 2003, 28:1265-1273.
84. Fountoulakis M., Cairns N., Lubec G. Increased levels of 14-3-3 gamma and epsilon proteins in brain of patients with Alzheimer's disease and Down syndrome. J Neural Trans 1999, 57:323-335.
85. Burkhard P.R., Sanchez J.C., Landis T., Hochstrasser D.F. CSF detection of the 14-3-3 protein in unselected patients with dementia. Neurology 2001, 56:1528-1533.
86. Fu H., Subramanian R.R., Masters S.C. 14-3-3 proteins: structure, function, and regulation. Annu Rev Pharmacol Toxicol 2000, 40:617-647.
87. Clayton D.F., George J.M. Synucleins in synaptic plasticity and neurodegenerative disorders. J Neurosci Res 1999, 58:120-129.
88. Murphy D.D., Rueter S.M., Trojanowski J.Q., Lee V.M. Synucleins are developmentally expressed, and alpha-synuclein regulates the size of the presynaptic vesicular pool in primary hippocampal neurons. J Neurosci 2000, 20:3214-3220.
89. Li J.Y., Henning Jensen P., Dahlstrom A. Differential localization of alpha-, beta- and gamma-synucleins in the rat CNS. Neurosci 2002, 113:463-478.
90. Rockenstein E., Hansen L.A., Mallory M., Trojanowski J.Q., Galasko D., Masliah E. Altered expression of the synuclein family mRNA in Lewy body and Alzheimer's disease. Brain Res 2001, 914:48-56.
91. Boyd-Kimball D., Sultana R., Poon H.F., Mohmmad-Abdul H., Lynn B.C., Klein J.B., et al. Gamma-glutamylcysteine ethyl ester protection of proteins from Abeta(1-42)-mediated oxidative stress in neuronal cell culture: a proteomics approach. J Neurosci Res 2005, 79:707-713.
92. Owen J.B., Di Domenico F., Sultana R., Perluigi M., Cini C., Pierce W.M., et al. Proteomics-determined differences in the concanavalin-A-fractionated proteome of hippocampus and inferior parietal lobule in subjects with Alzheimer's disease and mild cognitive impairment: implications for progression of AD. J Proteome Res 2009, 8:471-482.
93. Di Domenico F., Owen J.B., Sultana R., Sowell R.A., Perluigi M., Cini C., et al. The wheat germ agglutinin-fractionated proteome of subjects with Alzheimer's disease and mild cognitive impairment hippocampus and inferior parietal lobule: implications for disease pathogenesis and progression. J Neurosci Res 2010, 88:3566-3577.
94. Butterfield D.A., Abdul H.M., Opii W., Newman S.F., Joshi G., Ansari M.A., et al. Pin1 in Alzheimer's disease. J Neurochem 2006, 98:1697-1706.
95. Lu P.J., Wulf G., Zhou X.Z., Davies P., Lu K.P. The prolyl isomerase Pin1 restores the function of Alzheimer-associated phosphorylated tau protein. Nature 1999, 399:784-788.
96. Pastorino L., Sun A., Lu P.J., Zhou X.Z., Balastik M., Finn G., et al. The prolyl isomerase Pin1 regulates amyloid precursor protein processing and amyloid-beta production. Nature 2006, 440:528-534.
97. Liou Y.C., Sun A., Ryo A., Zhou X.Z., Yu Z.X., Huang H.K., et al. Role of the prolyl isomerase Pin1 in protecting against age-dependent neurodegeneration. Nature 2003, 424:556-561.
98. Walsh D.M., Klyubin I., Fadeeva J.V., Rowan M.J., Selkoe D.J. Amyloid-beta oligomers: their production, toxicity and therapeutic inhibition. Biochem Soc Trans 2002, 30:552-557.
99. Drake J., Link C.D., Butterfield D.A. Oxidative stress precedes fibrillar deposition of Alzheimer's disease amyloid beta-peptide (1-42) in a transgenic Caenorhabditis elegans model. Neurobiol Aging 2003, 24:415-420.
100. Klein W.L. Synaptic targeting by A beta oligomers (ADDLS) as a basis for memory loss in early Alzheimer's disease. Alzheimers Dement 2006, 2:43-55.